- Viking Therapeutics loses a third of its value after oral weight-loss drug trial MarketWatch
- Viking Therapeutics shares fall 40% on disappointing obesity pill trial data CNBC
- Viking Therapeutics (VKTX) Stock Fell More Than 30%. What Sent It Crashing. Barron’s
- Viking’s oral pill reduces up to 12.2% weight but shares slump on higher patient exits Reuters
- Viking Therapeutics Rises as Phase 3 Trials and Oral Formulation Progress Accelerate Yahoo Finance
Source link
